KRAS-driven treatment of NSCLC was implemented with BF006—novel lyophilized lipid NP formulation, which delivers a siRNA inhibiting the expression of glutathione-S-transferase P that is strongly up-regulated in KRAS mutated tumors [38]. Here, KRAS is linked to non-small cell lung carcinoma.